Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business
This article was originally published in The Gray Sheet
Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.
You may also be interested in...
Abbott’s FreeStyle Precision Pro blood glucose and beta-ketone monitoring system and Boston Scientific’s Rhythmia EP-mapping system earned 510(k) clearances. Also, Boston Sci’s OptiCross imaging catheter gained regulatory clearance in three countries. More new product news.
Boston Scientific is highlighting a secondary-endpoint analysis showing that the left-atrial appendage closure device reduced all-cause death by 34 percent. The company plans to submit a PMA for the device by the end of the second quarter.
Device therapies for atrial fibrillation (AF) have so far failed to result in compelling efficacy across all types of disease and patients. The rates of elimination of AF following a catheter ablation procedure range from 30% to 80% according to the type of patient and the definition of success. The question of why success rates aren’t yet sufficient after a great deal of investment is an area of active pursuit, and one that opens up the door for next-generation AF device companies seeking to improve upon the results achieved to date.